Clinical Double-Blind Randomized Controlled Trial of Quji Tongluo Decoction in Intervention of Branch Retinal Vein Occlusion Secondary Macular Edema

Eye Hospital, China Academy of Chinese Medical Sciences0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•1. Between 40 and 70 years old;
•2. It conforms to the Western medicine diagnostic criteria of non-ischemic branch retinal vein occlusion and conforms to the TCM syndrome differentiation criteria of phlegm and blood stasis. The course of the disease is more than 2 weeks;
•3. OCT examination showed macular edema, and the thickness of the central retina was more than 250µm;
•4. Agree to participate in this clinical trial and sign an informed consent form.

•1. There is severe turbidity of the refractive medium;
•2. Those with loss of central vision in the late course of the disease;
•3. Combined with other macular diseases of the retina;
•4. Persons who are allergic or possibly allergic to drugs;
•5. Patients suffering from severe cardiovascular and cerebrovascular diseases or severely impaired liver and kidney function and systemic failure, or combined with severe global diseases, cannot tolerate relevant eye examinations and surgical treatment;
•6. Women during pregnancy and lactation;
•7. Patients who are participating in clinical trials of other drugs or who have used similar Chinese medicines and other treatments.

发起方

Eye Hospital, China Academy of Chinese Medical Sciences